Posted by Michael Wonder on 07 Mar 2017
PBAC publishes final two outcomes from the November 2016 meeting
7 March 2017 - The outcomes for tolvaptan and trifluridine with tipiracil hydrochloride are now available.
Otsuka is seeking a PBS listing for tolvaptan (Jinarc) for the treatment of patients with autosomal dominant polycystic kidney disease. The PBAC deferred consideration of this item until the TGA evaluation has further progressed. The PBAC will consider the listing of tolvaptan at this week's meeting.
Servier is seeking a PBS listing for trifluridine with tipiracil hydrochloride (Lonsurf) for the treatment of patients with metastatic colorectal cancer (mCRC). The PBAC rejected the listing of trifluridine with tipiracil hydrochloride on the PBS for the treatment of patients with mCRC who have been previously treated with, or are not considered suitable for, currently available therapies. This decision was made on the basis of a modest clinical benefit, high and uncertain incremental cost-effectiveness ratio, and concern that the extent of benefit as observed in the clinical trial would not be realised in clinical practice. The PBAC will consider a resubmission for trifluridine with tipiracil at this week's meeting.
